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Purpose: Anthracyclines and taxanes are considered the standard for neoadjuvant chemotherapy 
of breast cancer, although they are often associated with serious side effects and wide variability 
of individual response. In this study, we analyzed the value of topoisomerase II alpha (TOP2A) 
and transducin-like enhancer of split 3 (TLE3) as predictive markers of response to therapy 
with anthracyclines and taxanes.
Materials and methods: TOP2A and TLE3 protein expressions were evaluated using immuno-
histochemistry on 28 samples, obtained by core needle biopsy in patients with locally advanced 
breast carcinoma, subsequently subjected to epirubicin- and paclitaxel-based neoadjuvant 
chemotherapy. The immunohistochemical staining was correlated with the clinical response 
measured by the tumor size reduction evaluated by breast magnetic resonance imaging, prior 
and after chemotherapy, and by pathologic evaluation of the surgical specimen.
Results: Neoadjuvant chemotherapy achieved a size reduction in 26/28 tumors (92.9%), with 
an average percentage decrease of 45.6%. A downstaging was achieved in 71.4% of the cases 
of locally advanced carcinoma. TOP2A positivity was correlated with a greater reduction in 
tumor diameter (P=0.06); negative staining for TLE3 was predictive of a better response to 
neoadjuvant chemotherapy (P=0.07). A higher reduction in tumor diameter (P=0.03) was also 
found for tumors that were concurrently TLE3-negative and TOP2A-positive.
Conclusion: TOP2A and TLE3 showed a correlation with response to neoadjuvant 
chemotherapy. While TOP2A is a well-known marker of response to anthracyclines-based 
chemotherapy, TLE3 is a new putative predictor of response to taxanes. Data from the current 
study suggest that TOP2A and TLE3 warrant further investigation in a larger series as predictors 
of response to neoadjuvant chemotherapy for locally advanced breast carcinoma.
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Introduction
Anthracyclines and taxanes are currently considered the gold standard for neo-
adjuvant chemotherapy of locally advanced breast cancer. However, preoperative 
treatment with these drugs may be associated with different degrees of response and 
sometimes with severe side effects. Taking into consideration the biological hetero-
geneity of breast cancer, which results in a wide variability of response, research 
has been focused on the identification of markers for prediction of the efficacy of 
chemotherapy based on such drugs, so that only the patients who can get benefit are 
subjected to the treatment.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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Human epidermal growth factor receptor 2 (HER2) gene 
amplification and/or HER2 overexpression have been identi-
fied as predictive markers of response to anthracycline-based 
chemotherapy.1,2 However, their role is still controversial.
Topoisomerase II alpha (TOP2A), encoded by a gene 
located on chromosome 17q12-q21, plays an essential 
function in cell proliferation by controlling the topological 
state and replication of deoxyribose nucleic acid (DNA).3 
Following the identification of TOP2A as the enzyme that 
produces the damage on DNA4,5 caused by anthracyclines, 
the focus has shifted on the study of the predictive value of 
TOP2A gene. Several studies suggested that the addition of 
anthracyclines in the treatment of breast cancer that showed 
amplification and/or deletion of TOP2A gene was associated 
with a better response to the therapy.6–10 The predictive role 
of TOP2A was also consistent with that of HER2, given 
the close localization of the two genes on chromosome 17. 
The study of Konecny et al reported that the benefits of 
anthracycline treatment were confined to the group of HER2-
positive tumors with concomitant amplification of TOP2A 
gene, thus demonstrating that TOP2A was more accurate as 
predictive marker than HER2.11 However, as the target of 
anthracyclines is the TOP2A protein and not the gene, and 
considering the poor correlation between gene amplification 
and overexpression of the protein, the levels of expression 
of the protein TOP2A have been hypothesized as even more 
precise markers.12
Despite numerous studies on this subject, no final verdict 
has been reached yet regarding the predictive role of TOP2A. 
Thus, the first objective of this study was to further analyze 
the predictive value of TOP2A protein.
The association of taxanes with anthracyclines has proved 
a more effective treatment regimen when compared to anthra-
cycline monotherapy associated with a higher percentage 
of pathological complete response (pCR) and conservative 
interventions.13 Taxanes cause apoptosis of tumor cells by 
stabilizing microtubules and inducing blockage in the G2/M 
phase of the cell cycle.14 Over the last years, various clini-
cal and pathologic parameters were analyzed to identify a 
parameter as a predictor of response to taxanes; among these, 
the focus was concentrated on protein Tau15 and, recently, 
on transducin-like enhancer of split 3 (TLE3).
The TLE3 is a member of the family of the transducin-
like enhancer of split, and is a transcriptional repressor 
homolog of the protein Groucho, which is a part of the 
Notch signaling cascade in Drosophila melanogaster16 that 
appears to be expressed periodically during the M phase of 
the cell cycle.17 The Notch signaling pathway controls the 
cellular interactions important for the differentiation target 
of many cells, prolonging the state of immature precursors 
until the correct morphogenetic signals, necessary for cell 
differentiation, are available. The TLE family proteins are 
part of the Notch signaling pathway in mammals, and TLE 
genes are coexpressed with Notch genes in immature pro-
liferative cells, thus confirming their role in the process of 
cell differentiation.18,19
TLE3 protein interacts directly with chromatin and 
chromatin-associated proteins, and it has been hypothesized 
to be a marker able to identify the cells that are particularly 
sensitive to taxane-mediated cell death.20,21
Up to date no biomarker of response to taxane che-
motherapy has been validated and introduced into clinical 
practice. The prognostic value of TLE3 in breast cancer has 
been analyzed so far in a single study, which suggested the 
association with a higher sensitivity to taxanes.21 Similar 
results have been published in non-small-cell lung cancer.22 
Therefore, the second goal of our study was to explore the 
predictive role of TLE3 protein expression in the neoadju-
vant setting.
Materials and methods
Patients
The study analyzed a group of 25 patients, treated in the 
period between December 2005 and December 2012 at the 
Breast Unit of the Department of Sciences for Woman’s 
and Child’s Health, University of Florence, suffering from 
locally advanced breast carcinoma or inflammatory cancer 
and initially candidates for mastectomy. Three of the patients 
had bilateral disease; therefore, the study was based on the 
analysis of 28 cases of breast cancer. All the patients gave 
informed consent to the use of part of their biological speci-
mens for research purposes. The study was approved by the 
local ethics committee.
The clinical and pathological characteristics of the 
patients are summarized in Table 1.
Treatment regimes
All the patients were subjected to a median number of four 
cycles of neoadjuvant chemotherapy (range two to eight 
cycles), administered every 21 days, containing epirubicin 
(75 mg/m2) and paclitaxel (175 mg/m2).
Before the start of neoadjuvant therapy, the patients 
underwent imaging studies, including breast ultrasound, mam-
mography, and contrast-enhanced breast magnetic resonance 
imaging (MRI), to obtain an accurate evaluation of tumors, 
with special regard to size and distribution of the lesions.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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immunohistochemistry
Before the start of neoadjuvant therapy, tumor samples were 
obtained by core needle biopsy for diagnostic and research 
purposes; the samples were then fixed in formalin and embed-
ded in paraffin, and then subjected to routine hematoxylin 
and eosin staining as well as to immunohistochemical (IHC) 
staining.
In four cases, paraffin-embedded tissue blocks, obtained 
prior to chemotherapy treatment, were not available. 
Therefore, IHC evaluation of the expression of TOP2A and 
TLE3 was carried out in 24 cases.
The TOP2A protein expression was evaluated using 
the mouse monoclonal antibody clone 3F6 (Santa Cruz 
Biotechnology Inc., Dallas, TX, USA) at a dilution of 1:50, 
following the instructions provided by the manufacturer. 
The number of stained nuclei in a total of 100 cells was then 
counted under a microscope, and the result was expressed as 
a percentage of positive cells.
Thus, a cut-off of 30%, corresponding to the median value 
of expression of TOP2A, was then chosen to define TOP2A-
positive ($30%) and TOP2A-negative (,30%) tumors 
(Figure 1). By this way, patients with TOP2A expression 
above the median of the study population were compared 
with those with lower immunostaining level.
The expression of TLE3 was evaluated by IHC staining 
with a rabbit polyclonal antibody (Santa Cruz Biotechnology) 
diluted to 1:200 following the instructions provided by the 
manufacturer. The count of stained nuclei was done and 
scored as previously described. In this case, after exploring 
different cut-off values, the cut-off value was chosen arbi-
trarily as negative versus positive (any staining) (Figure 2). 
The choice has been made in pursuit of optimization of the 
correlation between TLE3 protein expression and response 
to chemotherapy in terms of size reduction of the tumor.
statistical analysis
The response to neoadjuvant chemotherapy was evaluated 
in terms of percentage of the reduction in tumor size by 
measuring the largest diameter of the tumor before and after 
neoadjuvant therapy, using the information obtained from 
imaging techniques: ultrasound, mammography, and MRI. 
The final size of the tumor was measured by the pathologist 
on the surgical specimen.
The clinical outcome was evaluated by measuring the 
disease-free survival, defined as the time elapsed from 
the beginning of neoadjuvant therapy up to the date on which 
the development of a recurrence of cancer, both local or 
distant, was recorded, or the date of last follow-up visit.
Table 1 clinical and pathologic characteristics of the patients
Characteristic Number %
number of patients 28 100.0
age (years)
 , 50 18 64.3
 $ 50 10 35.7
clinical (T) stage
  T2 15 53.6
  T3 6 21.4
  T4d 7 25.0
lVsi
  negative 12 42.9
  Positive 16 27.1
Type of lesion
  Unifocal 9 32.1
  Multifocal 10 45.8
  Multifocal and multicentric 9 32.1
grade
 1 5 17.9
 2 9 32.1
 3 14 50.0
Tumor size before cTX
  20–30 mm 13 46.4
  31–50 mm 4 14.4
 . 50 mm 11 39.2
Pathological (ypT) stage
  ypT0 2 7.1
  ypT1 10 35.7
  ypT2 11 39.3
  ypT3 1 3.6
  ypT4 4 14.3
Tumor histology
  Ductal 12 42.9
  lobular 10 35.7
  Mixed 3 10.7
  Other 3 10.7
er status
  negative 7 25.0
  Positive 21 75.0
Pgr status
  negative 8 28.6
  Positive 20 71.4
her2 status
  negative 23 82.1
  Positive 5 17.9
Ki-67
 , 15% 11 39.3
 $ 15% 17 60.7
 , 50% 21 75.0
 $ 50% 7 25.0
Abbreviations:  cTX,  chemotherapy;  er,  estrogen  receptor;  her2,  human 
epidermal  growth  factor  receptor  2;  lVsi,  lymphovascular  space  invasion;  Pgr, 
progesterone receptor.
After the last chemotherapy cycle, all imaging studies 
were repeated to assess the response to neoadjuvant treatment 
in terms of reduction in tumor diameter. Then, a conservative 
surgical intervention or a mastectomy was planned, accord-
ing to the extent of response to neoadjuvant therapy and the 
breast size, as usual.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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A 
B 
Figure 1 immunostaining for TOP2a in preoperative breast cancer core biopsies.
Note: staining was (A) positive ($30% positivity) (×200) or (B) negative (,30% 
positivity) (×200).
Abbreviation: TOP2a, topoisomerase ii alpha.
A 
B 
Figure 2 immunostaining for Tle3 in preoperative breast cancer core biopsies. 
Note:  staining  was  (A)  positive  ($1%  positivity)  (×200)  or  (B)  negative  (null 
positivity) (×200).
Abbreviation: Tle3, transducin-like enhancer of split 3.
The median follow-up of patients was 36 months 
(range 12–103).
The frequency distribution of the studied parameters 
among the population was assessed by Fisher’s exact test or 
by chi-square test, as appropriate. The association of each 
variable with the reduction in tumor size was estimated by 
means of logistic regression. The disease-free survival was 
calculated according to the Kaplan–Meier method, and the 
differences were evaluated using the log-rank test.
All the statistical analyses were performed using IBM 
Statistical Package for the Social Sciences software, 
  version 21.
Results
Comparing the data obtained by imaging techniques before 
and after neoadjuvant chemotherapy with the pathological 
information from the surgical specimen, a reduction in tumor 
size was achieved in 26 of 28 cases (92.9%). The average 
size of tumors prior to chemotherapy treatment was 49.5 mm, 
while after the therapy 25.7 mm (Table 2), with an average 
percentage reduction by 45.6%.
In two cases (7.2%), a complete pathologic response 
(pCR) was achieved, evidenced by preoperative MRI and 
confirmed by histologic evaluation of the surgical specimen. 
The distribution of the cases according to percentage of size 
reduction is given in detail in Table 3.
Table  2  Tumor  diameter  before  and  after  neoadjuvant 
chemotherapy treatment
Tumor  
size (mm)
Before CTX After CTX
Number % Number %
0–19 – – 10 35.6
20–30 13 46.4 10 35.6
31–50 4 14.4 5 18.0
.50 11 39.2 3 10.8
Abbreviation: cTX, chemotherapy.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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In seven cases, the indication for neoadjuvant chemo-
therapy was represented by inflammatory breast carcinoma. 
All these cases underwent mastectomy, irrespective of the 
degree of response. Among the remaining 21 cases with 
locally advanced breast carcinoma, downstaging of the tumor 
was obtained in 15 of 21 cases (71.4%). So, after neoadjuvant 
chemotherapy, a breast conserving procedure was performed 
in 15 of 21 cases (71.4%).
By IHC, the average TOP2A protein expression was 
41% (standard deviation [SD] =26.4%), with a median of 
30%. Considering the median value as cut-off, we had eight 
TOP2A-negative cases (33.3%) and 16 TOP2A-positive 
cases (66.6%).
The average expression of TLE3 protein was 49% 
(SD =32.0%), with a median of 55%. We had three TLE3-
  negative cases (12.5%) and 21 TLE3-positive cases (87.5%).
To investigate the possible correlation between the IHC 
expression of TOP2A and TLE3 and response to neoadjuvant 
chemotherapy, taking into consideration that the average size 
reduction was 45.6%, we arbitrarily considered patients with 
size reduction $70% as good responders. Overall, 21.4% 
of the patients (6/28) were good responders, while 78.6% 
(22/28) obtained a reduction in tumor diameter ,70%.
To evaluate the predictive value of clinicopathological 
and IHC characteristics of tumors in the identification of 
good responders, a logistic regression analysis was carried 
out (Table 4).
Tumors with very low expression of progesterone recep-
tor (PgR ,10%) (P=0.04) and those with low expression 
of estrogen receptor (ER ,70%) (P=0.05) were associated 
with an increased sensitivity to neoadjuvant chemotherapy. 
Age was a predictive factor, in that patients $50 years old 
had a better response to therapy (P=0.01). TOP2A positiv-
ity ($30%) and TLE3 negativity were also associated with 
a marked response to neoadjuvant chemotherapy (P=0.06 
and P=0.07, respectively).
More detailed analysis of the association between TOP2A 
immunostaining with the extent of response to neoadju-
vant chemotherapy showed that 100% of good responders 
(  reduction $70%) were TOP2A-positive, while among those 
who did not get such reduction, 58% (11/19) were TOP2A-
positive (P=0.1). None of the TOP2A-negative patients 
achieved a marked response to chemotherapy (Figure 3).
TOP2A positivity was associated with a trend to show 
a better outcome in terms of disease-free survival (P=0.3) 
(Figure 4).
Table 3 Distribution by size reduction (%) after chemotherapy 
treatment
Size reduction (%) Number %
0–19 3 10.7
20–49 13 46.4
50–69 6 21.4
70–99 4 14.3
100 2 7.2
Table 4 Probability to obtain a tumor size reduction $70% after 
neoadjuvant chemotherapy according to clinical–pathological and 
ihc features (logistic regression analysis)
Characteristic Size reduction $70%
HR 95% CI P-value
age (years)
 , 50 1
 $ 50 17.0 1.59–181.36 0.01
er (%)
 , 70 1
 $ 70 0.14 0.02–1.05 0.05
Pgr (%)
 , 10 1
 $ 10 0.09 0.009–0.95 0.04
Tle3
  Positive 1
  negative 12.5 0.81–166.66 0.07
TOP2a
  negative 1
  Positive 9.0 0.88–91.25 0.06
Ki-67
 , 50% 1
 $ 50% 4.50 0.65–31.08 0.12
her2
  negative 1
  Positive 0.90 0.08–9.97 0.93
Triple-negative
  no 1
  Yes 3.16 0.39–25.57 0.27
grade
  1–2 1
  3 2.40 0.36–15.94 0.36
Pathological (ypT) stage
  T2 1
  T3–T4 3.16 0.39–25.57 0.27
lVsi
  negative 1
  Positive 0.28 0.04–1.92 0.19
Type of lesion
  not multicentric 1
  Multicentric 3.21 0.43–23.78 0.25
Tumor histology
  Ductal 1
  Others 0.28 0.04–1.92 0.19
Abbreviations:  CI,  confidence  interval;  ER,  estrogen  receptor;  HER2,  human 
epidermal growth factor receptor 2; hr, hazard ratio; lVsi, lymphovascular space 
invasion; Pgr, progesterone receptor; Tle3, transducin-like enhancer of split 3; 
TOP2a, topoisomerase ii alpha.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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Analysis of the TLE3 expression revealed that among 
good responder patients, 40% were TLE3-negative, in com-
parison with only 5% who did not achieve such a reduction 
(P=0.09) (Figure 5).
Finally, considering the subgroup of patients who were 
concurrently TOP2A-positive and TLE3-negative (n=2), all 
of them were good responder patients (P=0.03) (Figure 6) and 
were disease free at the end of follow-up period (Figure 7). 
Concerning the clinical outcome, the results confirmed the 
association between response to neoadjuvant chemotherapy 
resulting in downstaging of the tumor and disease-free 
survival. In fact, patients with ypT1–T2 disease behaved 
significantly better than those with ypT3–T4 stage disease 
after neoadjuvant treatment (P,0.001) (Figure 8).
Discussion
Our study confirmed the efficacy of epirubicin- and 
  paclitaxel-based neoadjuvant chemotherapy regimen in 
42%
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P=0.1
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n=8
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Figure 3 Distribution of good responders according toTOP2a status.
Abbreviation: TOP2a, topoisomerase ii alpha.
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Figure  6  Distribution  of  good  responders  according  to  concurrent  TOP2a 
positivity and Tle3 negativity.
Abbreviations: Tle3, transducin-like enhancer of split 3; TOP2a, topoisomerase 
ii alpha.
patients with locally advanced breast cancer, showing a 
reduction in tumor volume in almost all cases (26 out of 28 
patients, 92.9%), with an average size reduction by almost 
half (45.6%) (Table 3).23
Excluding cases of inflammatory breast cancer, the down-
staging was obtained in 71.4% of cases (15 out of 21 patients). 
The marked reduction in tumor size after neoadjuvant che-
motherapy resulting in downstaging confirmed its strong 
impact on clinical outcome (Figure 8). In addition, taking 
into consideration that before neoadjuvant chemotherapy all 
the patients were candidates for a mastectomy, this result has 
allowed sparing of mastectomy in favor of a breast conserving 
procedure in 71.4% of our patients. In agreement with our 
data, in the literature, there are several studies demonstrating 
the efficacy of preoperative chemotherapy in reducing tumor 
size and, consequently, in reducing mutilating interventions 
in favor of more conservative procedures, such as quadrant-
ectomy or tumorectomy.23–26
In the current series, we obtained a pCR in 7.1% of the 
patients (9.5% if we exclude patients with initial diagnosis 
of carcinomatous mastitis). Percentages of pCR following 
neoadjuvant chemotherapy for locally advanced breast cancer OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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reported in the literature are highly variable (4%–34%).25,26 
Such variability in the rate of pCR in the literature is probably 
due to different criteria used to define it, the heterogeneity 
of breast cancer biology, and the different systemic treat-
ments administered. The relatively low percentage of pCR 
obtained in this study could be explained by the accurate 
and intensive histological analysis of the surgical specimen 
performed by our pathologists, able to detect even minimum 
residual disease.
Concerning the cases of carcinomatous mastitis, the 
epirubicin- and paclitaxel-based regimen used in this study 
was effective as well, because all the patients, initially with 
inoperable cancer diagnosis, obtained a response allowing 
us at least to perform a mastectomy with axillary dissection 
having clear margins. This approach to the management of 
carcinomatous mastitis is currently the standard.27–29
Among predictors of response to neoadjuvant chemo-
therapy, we found that tumors with low expression of ER 
and PgR and patients aged .50 years had a significantly 
greater likelihood of achieving a marked volume reduction 
in response to anthracycline- and taxane-based chemotherapy 
(Table 4), in agreement with previous studies.30
Concerning the role of TOP2A and TLE3, our findings 
were encouraging, although the results only approached statis-
tical significance. The study searched for a correlation between 
the IHC expression of TOP2A and TLE3 with the reduction 
in tumor volume after chemotherapy and the disease-free 
survival. As far as TOP2A is concerned, analysis focused on 
the value of the expression of the TOP2A protein and not its 
gene amplification, as the target of anthracyclines is the protein 
and not the gene. Furthermore, it is well known that the relation 
between the amplification of TOP2A gene and the expression 
of TOP2A protein is poor, probably due to transcriptional and 
post-transcriptional protein degradation processes.31 In the 
current study, we found that IHC for TOP2A showed an aver-
age protein expression of 41% and a median of 30%, in line 
with the values reported in the literature.32–35 TOP2A positivity 
was associated with a nine-fold higher probability to obtain 
a good response (decrease in size $70%) (Table 4), although 
this result was of borderline statistical significance (P=0.06). 
In particular, all the patients who achieved a marked reduction 
in tumor size ($70%) were TOP2A-positive; by contrast, none 
of the TOP2A-negative patients achieved a marked response 
to chemotherapy (Figure 3). This result, however, was not 
statistically significant, possibly because of the low number 
of cases analyzed. In the literature, the studies that evaluated 
the role of TOP2A as predictor of response to neoadjuvant 
chemotherapy with anthracyclines provided heterogeneous 
result: in fact, some studies showed that the overexpression of 
TOP2A predicts a good clinical response to chemotherapy,33 
while others failed to demonstrate this correlation.34
In our study, we have identified a correlation between the 
overexpression of TOP2A and response to the therapy with 
anthracyclines in terms of reduction in tumor volume $70%. 
Our data suggest that TOP2A positivity, although indicat-
ing more likely to respond, does not confer the certainty of 
getting a good response (reduction $70%) to neoadjuvant 
chemotherapy based on anthracyclines. On the other hand, 
the negativity of TOP2A was associated with the lack of 
response. These results are in line with other studies claim-
ing that a decrease in expression of TOP2A protein confers 
resistance to anthracyclines.35
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Concerning clinical outcome, patients with TOP2A 
positivity showed a trend to develop fewer recurrences and 
to have a prolonged disease-free survival. However, the 
difference was not statistically significant in our data set, 
probably due to the low number of cases (Figure 4). Also in 
this case, the data reported in the literature are contradictory, 
with some clinical studies showing improved outcome after 
addiction of anthracyclines in TOP2A-positive patients,36 
while others negate this.37
Concerning TLE3, which was hypothesized as a possible 
marker of response to taxane-based chemotherapy, there 
are very few data in the literature. In our study, the average 
expression of the TLE3 protein was 49% (median 55%). 
We found a correlation between TLE3 negativity and good 
response to therapy. Hence, a reduction of tumor size $70% 
was likely to occur 12-fold more frequently among TLE3-
negative cases (Table 4). However, this result only approached 
statistical significance (P=0.07).
More in detail, two-thirds of TLE3-negative patients 
achieved a marked response to chemotherapy, while only 
14.2% of the TLE3-positive patients got such response 
(Figure 5). Also in this case, the results suggest that TLE3 
negativity does not confer the certainty of obtaining a high 
response to neoadjuvant chemotherapy, and TLE3 positiv-
ity predicts that, with high probability (85.8%), the patient 
will not get a marked size reduction. The limited number of 
cases in the study and especially the small sample of cases 
with TLE3-negative tumors greatly reduce the strength of 
our observations.
There is only one previous report on the expression 
of TLE3 as predictive marker of response to neoadjuvant 
chemotherapy with taxanes. That study was carried out by 
Kulkarni et al on a sample of 411 breast cancer patients, and 
they reported results in conflict with ours.21 In fact, they found 
that TLE3-positive tumors (IHC expression $30%) were 
associated with a greater reduction in tumor diameter, with a 
lower risk of recurrence after neoadjuvant chemotherapy, and 
with a better disease-free survival. It must be noted, however, 
that in the study of Kulkarni et al, only 23 patients received 
neoadjuvant chemotherapy as our cases, whereas the majority 
of the cases in their study did not. Therefore their results were 
not comparable with ours. Explanation for these conflicting 
results may be sought in the different types of antibody used 
for IHC analysis and/or the lack of a sufficiently standardized 
procedure for the allocation of the labeling percentage. Both 
our study and that of Kulkarni et al21 are based on a limited 
number of cases with neoadjuvant chemotherapy, which 
makes it impossible to draw definitive conclusions.
We also tried to combine the predictive value of TOP2A 
and TLE3. Considering the group of patients with tumors 
that were concurrently TLE3-negative and TOP2A-positive, 
we found that all the patients with such characteristics were 
good responders to neoadjuvant chemotherapy (reduction 
in size $70%) (Figure 6), whereas only 13.6% of patients 
without these characteristics got a marked response to neoad-
juvant chemotherapy (P=0.03). Similarly, all the patients with 
TLE3-negative and TOP2A-positive tumors were disease free 
at 5-years follow-up, in contrast with a disease-free survival 
of only 58% for all the other patients (Figure 8). This result 
was very intriguing. However, because the number of cases 
with TLE3-negative and TOP2A-positive tumors was very 
little in the current study (n=2, 8.3%), this finding should be 
interpreted with caution. All together, these results suggest 
that immunostaining for TOP2A and TLE3 may provide 
useful information as predictive markers of response to 
neoadjuvant chemotherapy based on anthracyclines and 
taxanes. The possible role of concomitant TLE3 negativity 
and TOP2A positivity as predictor of response to neoadjuvant 
chemotherapy in breast carcinoma warrants further investiga-
tion in a larger series.
Conclusion
This mono-institutional study showed that TOP2A posi-
tivity and TLE3 negativity were both associated with a 
better response to neoadjuvant chemotherapy based on 
anthracyclines and taxanes. These IHC characteristics, 
especially when concurrently present, correlated to a better 
outcome too. However, probably because of a relatively 
small number of patients, statistical significance was not 
always achieved.
Therefore, though some evidence that emerged from 
our study is suggestive, our results do not support routine 
use of TOP2A and TLE3 as predictors of response to neo-
adjuvant chemotherapy with anthracyclines and taxanes. 
Nonetheless, considering that this was the first study that 
investigated the role of concomitant evaluation of TOP2A 
and TLE3 as markers of response to neoadjuvant chemo-
therapy, further studies are needed, based on larger series 
of patients and possibly with a multicenter approach, to 
provide a clear answer to the growing demand of markers 
useful for the personalization of neoadjuvant treatment of 
breast cancer.
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